The functional and clinical roles of osteopontin in cancer and metastasis.

London Regional Cancer Centre, Ontario, Canada.
Current Molecular Medicine (Impact Factor: 3.61). 12/2001; 1(5):621-32. DOI: 10.2174/1566524013363339
Source: PubMed

ABSTRACT Osteopontin (OPN) is a secreted and integrin-binding protein that has been implicated in a number of pathologies. In this review we will focus on the functional and clinical roles of OPN in cancer and metastasis, with a particular emphasis on breast cancer. While much evidence has suggested that OPN is associated with cancer, its functional contribution to cancer remains poorly understood. Here we will review evidence for mechanisms by which OPN may act to enhance malignancy, including evidence that signaling pathways directly induced by OPN, as well as interactions with growth factor receptor pathways, can combine to activate expression of genes and functions that contribute to metastasis. OPN has been shown to be over-expressed in a variety of human tumors and is present in elevated levels in the blood of some patients with metastatic cancers. We also will discuss recent clinical evidence that suggests that OPN is not only associated with several tumor types, but that levels of OPN in cancer patients' blood or tumors may provide prognostic information.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim: To investigate role of the Osteopontin (OPN) genetic polymorphisms in the susceptibility to gliomas and their prognosis. Methods: A total of 248 Chinese glioma patients and 281 age and sex matched healthy controls were recruited. The genetic polymorphisms at three loci, namely, -156 GG>G, -443 C>T and -66T>G, were determined. The log-rank test and Kaplan- Meier analysis were introduced to assess the effect of OPN gene polymorphisms on patient survival. Results: We found that the genotype frequencies of OPN -443 C>T polymorphism were significantly different between glioma patients and controls. Multivariable analyses showed a higher risk for gliomas in -443 CC genotype carriers compared to -443TT carriers (P<0.001). In addition, we also found the OPN -443 C>T polymorphism was closely related to the gliomas' tumor grade. The -443 C>T polymorphism also affected the tumor OPN expression level, but not the serum OPN level. More importantly, the -443 C>T polymorphism was significantly associated with the prognosis of these patients regardless of their treatment status. The patients with -443CC genotype had a poorer prognosis than those with -443TT and -443CT genotypes. In contrast, the -156 G>GG and -66T>G polymorphisms were not associated with risk, clinical characteristics, or prognosis of gliomas. Conclusion: This study suggests that the -443C>T gene polymorphisms may be used as a molecular marker for glioma occurrence and clinical outcome in glioma patients. © 2014 S. Karger AG, Basel.
    Cellular Physiology and Biochemistry 09/2014; 34(4):1190-1198. DOI:10.1159/000366331 · 3.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteopontin (OPN) is a glycoprotein expressed by various tissues and cells. It is also implicated in tumor progression. The protein can mediate cell adhesion and is strongly associated with transformation and tumorigenesis. Overexpression of OPN influences invasion and metastasis of different human tumors, and OPN expression may be use as a possible prognostic marker. It has been detected in a growing number of human tumor types, by immunohistochemistry on tumor tissue sections. The objective of this study was to assess the immunohistochemical expression of OPN in different canine and feline tumors and to examine any possible relation with malignancy. To achieve these aim 40 different kinds of canine and feline tumors were evaluated. OPN was either not expressed or at low levels in benign tumors, but strongly expressed in malign tumors. This study showed that OPN may be associated with malignancy of cat and dog tumors. Keywords: Osteopontin (OPN), immunohistochemistry, dog, cat, tumor
    Revue de médecine vétérinaire 01/2015; 1-2:2-10. · 0.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 1. PSA in Screening for Prostate Cancer: More Good than Harm or More Harm than Good? 2. Ovarian Cancer Biomarkers: Current State and Future Implications from High-Throughput Technologies 3. Procollagen Assays in Cancer 4. Metabolomics in Dyslipidemia 5. Metabolism in Chronic Fatigue Syndrome 6. Cellular Regulation of Glucose Uptake by Glucose Transporter GLUT4 7. Identifying and Reducing Potentially Wrong Immunoassay Results Even When Plausible and “Not-Unreasonable”
    Advances in clinical chemistry 04/2014; 66:1-294. · 4.30 Impact Factor